Can I read Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study on EtoBox?

Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study by Wang, Peng; Gu, Jin; Yang, Juan; Yang, Chi; Wu, Xiaocui; Yu, Fangyou; Fan, Lin is a scholarly article available to read on EtoBox.

What is Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study about?

## Background: Re-treatment pulmonary tuberculosis (ptb) has a high risk of being multi-drug- or rifampicin-resistant tuberculosis (mdr/rr-tb). the xpert mtb/rif assay possesses high efficacy for the evaluation of rifampicin resistance. the aim of the present study was to assess the benefit of the xpert mtb/ rif assay in the screening and treatment of mdr/rr-tb in re-treatment ptb patients. ## Methods: Patients with suspected re-treatment ptb were prospectively enrolled and divided into xpert mtb/rif and mycobacterial tuberculosis (mtb) culture groups. no xpert mtb/rif assay was carried out in the mtb culture group. the diagnostic performance and turn-around time (tat) of mdr/rrtb detection and the culture results of mdr/rr-tb patients following two-month chemotherapy in two groups were calculated and compared. ## Results: Using phenotypic dst as a reference standard, the positive predictive value of xpert mtb/rif for the detection of rr-tb and mdr-tb among re-treatment ptb patients was 90.72% and 77.32%, respectively. the xpert mtb/rif group had a significantly shorter interval for the initiation of anti-mdr/ rr-tb treatment {1 [1-1] vs. 52 [47-57] days, p<0.0001}; and following t

Author

Wang, Peng; Gu, Jin; Yang, Juan; Yang, Chi; Wu, Xiaocui; Yu, Fangyou; Fan, Lin

Publisher

AME Publishing Company (ISSN 2224-5820)

Published

2020

Language

EN